Trial Profile
A Single Arm, 3 Phase Study to Determine the Effect of Intermittent Dosing of Rifampicin on the Pharmacokinetics of Raltegravir in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Rifampicin
- Indications HIV-1 infections; Tuberculosis
- Focus Pharmacokinetics
- Acronyms RIFRAL
- 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
- 03 Jul 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
- 02 May 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network record.